Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

³úÁ¹Áß È¯ÀÚÀÇ ´ç´¢º´ ¾à¹° ¿ä¹ý Pharmacotherapy of Diabetes Focused on Strok

´ëÇѽŰæ°úÇÐȸÁö 2019³â 37±Ç 3È£ p.235 ~ 250
·ù¿µ»ó, ±èÁøÈ­, ±è»ó¿ë,
¼Ò¼Ó »ó¼¼Á¤º¸
·ù¿µ»ó ( Lyu Young-Sang ) 
Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ Á¶¼±´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú

±èÁøÈ­ ( Kim Jin-Hwa ) 
Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ Á¶¼±´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú
±è»ó¿ë ( Kim Sang-Yong ) 
Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ Á¶¼±´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú

Abstract


Cardiovascular disease, including stroke, is one of the major causes of death in diabetes. Numerous studies have long suggested reducing macrovascular complication such as ischemic vascular disease through intensive glycemic control, but none was successful proving the effect of glycemic control. Recently, new possibilities in cardiovascular disease reduction have been proposed through cardiovascular safety trials of newly developed anti-hyperglycemic agents. The purpose of this review is to introduce the traditional and newly developed anti-diabetic medications and review their effects regarding cardiovascular outcomes mainly focusing on stroke.

Å°¿öµå

Diabetes mellitus; Stroke; Diabetes complications; Hypoglycemic agents

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS